Pfizer and Biontech expand study of vaccines for children

The New York Times reports that vaccine studies involving children aged 5-11 will be made more comprehensive in the wake of a request from the FDA.
Photo: Dado Ruvic/REUTERS / X02714
Photo: Dado Ruvic/REUTERS / X02714
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Vaccine trials for children aged 5-11 should be more comprehensive. For this reason, studies of the Pfizer-Biontech vaccine and the Moderna vaccine within this group will now be expanded, writes the New York Times.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading